News
Recall of anaemia drug highlights safety issues of NBCDs
2013-08-14 US-based biotech firm Affymax announced on 24 February 2013 that it is recalling all lots of its red blood cell-stimulating medicine Omontys (peginesatide). This could… Read More »
Research on biosimilars in anaemia and diabetes
2013-08-12 Period: September to December 2012 The use of biological medicines has been life-changing for many patients suffering with anaemia and diabetes. With the expiration of… Read More »
Huge differences in prescription drug prices in Ireland
2013-08-09 A survey carried out by Ireland’s National Consumer Agency (NCA) has found that the price of many commonly prescribed medicines varies widely across Ireland. The… Read More »
US FTC sides with generics makers over drug samples
2013-08-07 The US Federal Trade Commission (FTC) has come out in support of generics companies trying to get hold of brand-name drugs in order to make… Read More »
Biosimilar G-CSF prescribed more than originator
2013-08-05 Sandoz, the generic drug division of Swiss drug giant Novartis, announced on 22 July 2013 that its biosimilar granulocyte colony-stimulating factor (G-CSF) Zarzio (filgrastim) has… Read More »
Generics drugmakers should be held responsible for injuries
2013-07-26 In the long saga of generics pre-emption, The New York Times is adding its opinion to the argument of whether generics makers are liable for injuries caused… Read More »
Use of generic medicines in Ireland
2013-07-24 Ireland’s Department of Health and Children intends to introduce a system of reference pricing and generics substitution in Ireland, which will greatly increase the utilization… Read More »
Why choose generic medicines initiative launched in Australia
2013-07-22 The Australian Generic Medicines Industry Association (GMiA) and the Pharmacy Guild of Australia announced on 22 March 2013 the launch of a joint initiative: Why… Read More »
US state biosimilar substitution bill becomes law
2013-07-19 On 21 March 2013, the US State of Virginia signed into law a legislation allowing for the substitution of biosimilars, but with many restrictions, making… Read More »
Biosimilars in rheumatology
2013-07-17 Patents on key biological medicines used in rheumatology will expire soon. The European Medicines Agency’s (EMA’s) finalized guidelines on biosimilar monoclonal antibodies (mAbs) came into… Read More »
